Skip to main content

Iqvia Holdings Inc(IQV-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low173.93
Day High179.65
Open:178.20
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

TOP STORIES: Iqvia Holdings Inc

Select a category then submit the form to load news
IQVIA Holdings (IQV) Gets a Hold from Citi
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), RxSight (RXST) and Cardiff Oncology (CRDF)
Truist Financial Sticks to Its Buy Rating for IQVIA Holdings (IQV)
IQVIA Holdings Earnings Call Signals AI-Driven Growth
Jefferies Reaffirms Their Buy Rating on IQVIA Holdings (IQV)
Analysts Have Conflicting Sentiments on These Healthcare Companies: IQVIA Holdings (IQV) and Molina Healthcare (MOH)
Analysts’ Opinions Are Mixed on These Healthcare Stocks: IQVIA Holdings (IQV), Qiagen (QGEN) and Ligand Pharma (LGND)
Analysts’ Opinions Are Mixed on These Healthcare Stocks: IQVIA Holdings (IQV), Ocular Therapeutix (OCUL) and Arrowhead Pharmaceuticals (ARWR)
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), Haemonetics (HAE) and Denali Therapeutics (DNLI)
Barclays Keeps Their Hold Rating on IQVIA Holdings (IQV)
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), Omnicell (OMCL) and MiMedx Group (MDXG)
Analysts Offer Insights on Healthcare Companies: Elanco Animal Health (ELAN), IQVIA Holdings (IQV) and Ascendis Pharma (ASND)
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), Cencora (COR) and Radnet (RDNT)

Profile

IQVIA Holdings Inc. provides advanced analytics, technology solutions and contract research services to the life sciences industry. The company was formed through the merger of IMS Health (RX) and Quintiles. The company is focused on helping healthcare clients to better serve patients by bringing in updated and innovative ideas in the process of clinical development and commercialization, speed innovation and accelerate improvements. I